ZIM Laboratories Ltd

Stage 2 · Advancing · week 21Setup 8.3 ★★★ PrimeStrong +13.2

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. More about the company

₹146.6
+5.80% today
₹785 Cr · Small cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
0.0%
₹60.3 lo₹146.6 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 21
1w13w26w
Week 21 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
51.3%
200 DMA: ₹96.9 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
8.44x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
MA20 trending up · +4.6% vs MA50 +5.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+16.8%
3M
+23.9%
6M
+114.2%
YTD
+105.2%
1Y
+105.0%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
This stock ranks #8 of 77 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Ranks #8 of 61 Stage 2 stocks in this industry. Top tier.
Stage Cycle Timeline2023-07-12 → 2026-10-07
S3 16w
S4 19w
S4 19w
S2 21w
2023-07-122026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 9w → S2 5w → S3 16w → S4 13w → S1 10w → S4 3w → S1 2w → S2 6w → S3 6w → S4 2w → S3 2w → S2 4w → S4 19w → S1 6w → S2 5w → S3 2w → S4 19w → S1 7w → S4 7w → S1 2w → S2 21w current
Total tracked: 168 weeks across 21 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-07
Pullback Hunter
Latest: 2026-07-28
60 appearances in last 60 days. First seen: 2026-07-02.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S2
Wk 21 · Vol 8.44x
2026-10-06S2
Wk 21 · Vol 0.64x
2026-10-05S2
Wk 21 · Vol 0.80x
2026-10-01S2
Wk 21 · Vol 1.36x
2026-09-30S2
Wk 20 · Vol 0.94x
2026-09-29S2
Wk 20 · Vol 1.34x
2026-09-28S2
Wk 20 · Vol 1.26x
2026-09-25S2
Wk 20 · Vol 2.06x
2026-09-24S2
Wk 20 · Vol 1.05x
2026-09-23S2
Wk 19 · Vol 1.41x
2026-09-22S2
Wk 19 · Vol 0.68x
2026-09-21S2
Wk 19 · Vol 0.91x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
SHILPAMED
wk 22 · -0.2% from hi
8.0
Moving averages & range
50 DMA
₹125.3
200 DMA
₹96.9
52W High
₹146.6
52W Low
₹60.3
5D Low
₹137
Resistance levels (recent highs)
20d High
₹146.6
60d High
₹146.6
120d High
₹146.6
250d High
₹146.6
Next resistance
Above all
Ask the Market AI about ZIMLABAsk →
P/E (TTM)
85.8
Forward —
Earnings Growth (YoY)
+20.8%
Revenue -3.3%
ROE
+2.1%
Profit margin +1.6%
About this companyHealth Care· Pharmaceuticals

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.